# OnCo record nct05566041 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05566041/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05566041", "NCT05566041" ;
  schema:name "A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer"@en ;
  schema:alternateName "REPLATINUM"@en ;
  schema:description "A phase 3 trial of Etoposide, Carboplatin and Cisplatin in small-cell lung cancer, run by EpicentRx, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05566041/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05566041> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-08-01" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/epicentrx/> .